News

In this analysis presented at Maui Derm, indirect comparisons were made between risankizumab and icotrokinra in patients with psoriasis.

January 2025 saw new data and guidelines in asthma, COPD, and pulmonary fibrosis.

FDA clears pediatric HAE oral therapy as intranasal epinephrine and heat-treated peanut/egg OIT studies point to safer allergy care.

Eliezer Katz, MD, says investigational anti-CD40L therapy tegoprubart shows promise as a non-calcineurin inhibitor option for adult de novo kidney transplant patients

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

Anouti describes clinical uncertainties regarding signs of cholestatic liver disease, like jaundice, in patients with skin of color, and how this may impact transplant outcomes.

AbbVie’s upadacitinib (Rinvoq) has had its regulatory applications submitted to the FDA and the EMA, with the drug being indicated for adults and adolescents with vitiligo.

These data from the ongoing VESPER-3 phase 2b study highlight PF’3944’s capacity for reducing weight across 4 weekly-monthly dosing arms.

This Q&A interview with Drew Kuraitis, MD, PhD, highlights Kuraitis’s talk on strategies for cutaneous adverse events linked with therapeutic agents in oncology.

TACITO phase 2a suggests an improvement in clinical outcomes for patients with mRCC with fecal microbiota transplantation

Greene discusses his recent study highlighting the limitations of quadruple therapy in reducing mortality and hospitalization rates among patients with HFrEF.

Recent pooled analysis data suggest consistently low adverse event rates with upadacitinib over 7 years for patients with atopic dermatitis.

Catch up on disparities in IBD care, a potential new IBS drug, new insight on diet’s role in Crohn’s disease care, & more.

Catch up with major FDA decisions, key guidelines updates, and more.

The resubmission follows a prior Complete Response Letter (CRL) that identified chemistry, manufacturing, and control (CMC) issues.

FDA decisions, KDIGO guidelines, and federal nutrition updates redefine kidney care in January 2026

These new phase 2 INTEGUMENT-INFANT study findings point to the efficacy and safety of roflumilast cream 0.05% (Zoryve) in infants with eczema.

The CRL cited deficiencies limited to packaging and administration, with resubmission expected as early as Q3 2026.

Lee explains how understanding immune responses years before Crohn’s symptoms may open the door to earlier intervention and prevention strategies.

Freedman discusses a new analysis of the CARDIA study that indicates male patients’ greater risk of CHD at younger ages.

Although patients with remitted MDD showed greater impulsivity than controls, a study found no link between delay discounting and relapse risk after stopping antidepressants.

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

Lee explains what is known about the preclinical phase of Crohn’s disease before symptoms appear and describes his study on the role immune dysregulation plays.

Meta-analysis links longer preparation therapy and follow-up duration to depressive symptom change in psilocybin- and LSD-assisted treatment.

The Maui Derm Hawaii 2026 conference featured a poster presentation highlighting recent phase 3 findings on risankizumab in pediatric patients.

In this segment, Nancy Reau, MD, and Kimberly Brown, MD, discuss ongoing challenges with viral hepatitis elimination efforts and clinical shortcomings in screening.

New data suggest asthma-related depression may be biologically distinct from MDD, with greater serum BDNF tied to worse disease severity and lower physical activity.

Since 1990, the prevalence of individuals with a BMI ≥30 has increased dramatically, and without significant intervention, will continue to do so.